Recurrent or Metastatic NSCLC Patients With Classical EGFR Mutations Accompanied by MET Amplification or Overexpression
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Glumetinib Combined With Osimertinib Treatment for Non-Small Cell Lung Cancer Patients (NCT06908772) | Shanghai JMT-Bio Inc. | 2025-04-01 |
Track Recurrent or Metastatic NSCLC Patients With Classical EGFR Mutations Accompanied by MET Amplification or Overexpression automatically
Every clearance here is in the API, with alerts when new ones post.